Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598897 · ClinicalTrials.gov registry record · Phase 4
Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease
A Phase 4 study of Mycobacterium Avium Complex Lung Disease, sponsored by The University of Texas Health Science Center at Tyler.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT00598897: Completed Phase 4 study of Mycobacterium Avium Complex Lung Disease, sponsored by The University of Texas Health Science Center at Tyler.
NCT00598897 is a Phase 4 study of Mycobacterium Avium Complex Lung Disease that has completed, run by The University of Texas Health Science Center at Tyler. The registered enrollment target is 89 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00598897, a Phase 4 study of Mycobacterium Avium Complex Lung Disease, has completed, sponsored by The University of Texas Health Science Center at Tyler.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety and tolerance of clarithromycin given three times per week in combination with multiple drugs including rifabutin three times per week
Primary Outcome
sputum conversion culture neg x3
Conditions Studied
Interventions
- DRUG clarithromycin, rifabutin
Study Locations (1)
Texas
- The University of Texas Health Science Center at Tyler - Tyler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 1995-08 |
| Est. Completion | 2017-05-18 |
| Phase | Phase 4 |
What the finished NCT00598897 record still lists
NCT00598897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Mycobacterium Avium Complex Lung Disease appearing as the primary indexed condition, and to 1 intervention - of which clarithromycin, rifabutin is the first listed.
NCT00598897 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00598897 about?
NCT00598897 is a clinical study titled "Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease". To determine the safety and tolerance of clarithromycin given three times per week in combination with multiple drugs including rifabutin three times per week
What is the current status of trial NCT00598897?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 1995-08. Estimated completion is 2017-05-18.
What conditions does trial NCT00598897 study?
This clinical trial studies the following conditions: Mycobacterium Avium Complex Lung Disease.
What interventions are being tested in trial NCT00598897?
The interventions under investigation include: clarithromycin, rifabutin (DRUG).
Who is sponsoring clinical trial NCT00598897?
This trial is sponsored by The University of Texas Health Science Center at Tyler, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00598897 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00598897's enrollment target sits among peer trials
89 913th of 2000 higher than 1,086 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia